Hospice Benefits and Phase I Cancer Trials [5] (multiple letters)

Annals of Internal Medicine

Volumn 140, Issue 1, 2004, Pages 70-71

  Avery, Robert ^a   Trump, Donald L ^b   Byock, Ira ^c   Miles, Steven H ^d  

^a St Louis Oncology Associates   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MONTANA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG SAFETY; DYING; HOSPICE; HOSPICE CARE; HUMAN; INFORMED CONSENT; LETTER; MAXIMUM TOLERATED DOSE; MEDICARE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; BIOMEDICAL AND BEHAVIORAL RESEARCH; DEATH AND EUTHANASIA; ETHICS; NOTE; UNITED STATES;

BIOMEDICAL AND BEHAVIORAL RESEARCH; DEATH AND EUTHANASIA;

CLINICAL TRIALS, PHASE I; HOSPICE CARE; HUMANS; UNITED STATES;

EID: 0346727457     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-140-1-200401060-00028     Document Type: Letter

References (0)